Indefinite Delivery Contract 75D30123D16728
Award Date
7/1/23
Last Date to Order
6/30/24
Federal Agency
CDC Pittsburgh
Awardee
Grifols USA LLC
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
This federal contract indefinite delivery vehicle (IDV) was awarded to Grifols USA LLC by the Department of Health and Human Services (HHS) Centers for Disease Control and Prevention (CDC) to provide a variety of adult vaccines. The contract has a potential value of $1,647,100 and a period of performance from July 1, 2021 to June 30, 2022. The vaccines to be supplied under this IDV include hepatitis, pneumococcal, tetanus/diphtheria, herpes zoster, measles/mumps/rubella, meningococcal, human...
The Centers for Disease Control and Prevention (CDC) awarded a $1,727,800 indefinite delivery contract to Grifols USA LLC, a global healthcare company, to purchase 12 standard adult vaccines. The contract has a one-year period of performance from July 1, 2022 to June 30, 2023 and is not designated with any set-aside provisions. The vaccines are required to have a minimum 12-month shelf life and be delivered within 15 business days of order. The vaccines will support CDC immunization awardees,...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC, a foreign-owned, for-profit pharmaceutical company, to supply a variety of adult vaccines over a one-year period from July 1, 2023 through June 30, 2024. The total contract ceiling value is $232,487,206.61. The contract covers the procurement of an estimated 1.5 to 3 million doses of 12 different adult vaccines, including hepatitis A, hepatitis B, hepatitis A &...
The Centers for Disease Control and Prevention awarded multiple indefinite-delivery, indefinite-quantity contracts valued at up to $25,350,000 to supply adult vaccines for the period of July 1, 2023 through June 30, 2024. The prime contractor is VBI Vaccines (Delaware) Inc. The contracts aim to procure minimum and maximum quantities of 12 adult vaccines, including hepatitis A, hepatitis B, pneumococcal polysaccharide, tetanus and diphtheria toxoids, herpes zoster, measles, mumps and rubella,...
The Centers for Disease Control and Prevention awarded multiple indefinite delivery contracts under a competitive solicitation to purchase standard adult vaccines. The contracts have a one year period of performance from July 1, 2022 to June 30, 2023 and a combined potential value of $85.6 million. Merck Sharp & Dohme LLC was awarded one of these contracts as the prime contractor. The contracts enable the CDC to order 12 types of adult vaccines for delivery within 15 business days....
The Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) has awarded a 5-year, $154.3 million indefinite delivery, indefinite quantity (IDIQ) contract to Glaxosmithkline, LLC for the provision of various adult vaccines. The contract period of performance is from July 1, 2024 to June 30, 2025, with vaccines ordered via the CDC's Vaccine Tracking System (VTrckS) using a fair opportunity process. The required vaccine types include...
The Centers for Disease Control and Prevention awarded Grifols USA LLC an indefinite delivery contract for 2019 adult vaccines. The multiple award IDC has a potential value of $1,602,700 and a period of performance from July 1, 2019 through June 30, 2020. Grifols will supply various adult vaccines to support public health programs through the CDC. As a manufacturer of pharmaceuticals and medical products, Grifols has extensive experience providing specialized drugs, vaccines, immunoglobulins and...
The Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) awarded an Indefinite Delivery/Indefinite Quantity (ID/IQ) contract to Bavarian Nordic, Inc. for the procurement of various adult vaccines. The $99,015,000 multiple-award contract has a period of performance from July 1, 2024 to June 30, 2025. The contract does not utilize any set-asides. The solicitation seeks the purchase of vaccines for Hepatitis A, Hepatitis B, Hepatitis...
The Centers for Disease Control and Prevention (CDC) has awarded an Indefinite Delivery, Indefinite Quantity (IDIQ) contract to Dynavax Technologies Corporation, valued at up to $56,203,651.08, to supply various adult vaccines over a one-year period from July 1, 2023 through June 30, 2024. The vaccines to be delivered include hepatitis A, hepatitis B, hepatitis A & B combination, pneumococcal polysaccharide, tetanus and diphtheria toxoids, herpes zoster, tetanus, reduced diphtheria toxoid...
The Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) awarded an Indefinite Delivery Indefinite Quantity (IDIQ) contract worth up to $58,450,000 to Dynavax Technologies Corporation (Dynavax) for the purchase of various adult vaccines. The contract has a period of performance from July 1, 2024 to June 30, 2025 and is not set-aside. The required vaccine types include Hepatitis A, Hepatitis B, Hepatitis A&B combination, Herpes...